Skip to main content
Premium Trial:

Request an Annual Quote

Incogen Gets $2M from NCI for Cancer Diagnostic Software Development

NEW YORK, April 19 (GenomeWeb News) - Incogen said today that it has received a $2 million Phase II grant from the National Cancer Institute to develop its cancer diagnostic software.

 

The company will work with the Collegeof Williamand Mary and the EasternVirginiaMedicalSchoolon the project.

 

The two-year grant follows on a Phase I grant awarded to Incogen a year ago, which funded the development of a pilot project to analyze proteomics data produced by Ciphergen Biosystems' SELDI platform. In the second phase of the project, Incogen hopes to develop a clinical diagnostic software package for distribution to clinical researchers.

 

EVMS will produce the data for the project, while W&M and Incogen will analyze the data, the company said.

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.